James Allison Discusses the Potentiation of Checkpoint Blockage with Oncolytic Viruses

James P. Allison, PhD
Published: Tuesday, Aug 05, 2014

James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic viruses.

The checkpoint blockage works by enhancing priming of T cells when tumor cells are being killed, which causes an inflammatory response, Allison says. Oncolytic viruses either cause an innate immune response or kill the tumor cells while excreting antigens that lead to more priming of T cells.

Allison says research has shown that when a virus accomplishes both of these things, the priming of the T cells can be potentiated by immune checkpoint blockade.

Researchers are working on a second generation of oncoloytic viruses that cause co-stimulation of T cells, which will increase the efficacy, Allison says.

James P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, Giant of Cancer Care, discusses the potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic viruses.

The checkpoint blockage works by enhancing priming of T cells when tumor cells are being killed, which causes an inflammatory response, Allison says. Oncolytic viruses either cause an innate immune response or kill the tumor cells while excreting antigens that lead to more priming of T cells.

Allison says research has shown that when a virus accomplishes both of these things, the priming of the T cells can be potentiated by immune checkpoint blockade.

Researchers are working on a second generation of oncoloytic viruses that cause co-stimulation of T cells, which will increase the efficacy, Allison says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x